Clinical Research

There are no active Atopic Dermatitis studies at this time. Please check back again in the future.

Study Title: Study of NKX019, a CD19 Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy, in Subjects with Immune-Mediated Diseases

We are conducting a research study on individuals with immune-mediated diseases, including dermatomyositis and other idiopathic inflammatory myopathies. The purpose of this study is to learn more about the safety and efficacy of an investigational cell therapy medication called NKX019.

Participant requirements:

• 18 years of age or older
• Confirmation of dermatomyositis or another idiopathic inflammatory myopathy
• Attend 15 visits over 6 months, including 3 overnight hospital stays, and then annually for up to 15 years
• Other requirements, which the study team will review with you

This study is being conducted by Dr. David Pearson in the University Of Minnesota Department Of Dermatology. For additional information, please contact the study coordinator: 612-625-2624 or [email protected]

Study Title: 

A Study of 2 Doses of Ritlecitinib in People 12 - 17 With Alopecia Areata

We are looking for participants in a new study for Alopecia Areata. More information is available at the link.

________________________________________________________________________________________________

Study Title: 

A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients with Severe Alopecia Areata with an Open Label Extension Period

We are conducting a research study for individuals with severe Alopecia Areata. The purpose of this research study is to learn more about the safety and effectiveness of an investigational drug. This study will compare the investigational drug, Deuruxolitinib to a placebo.

Participant requirements:

• Adolescents’ male and female ages 12-17 years of age who are in good health
• Diagnosed with severe or very severe Alopecia Areata and have greater than or equal to 50% scalp hair loss
• Must be willing to stop using other types of medications to treat Alopecia Areata throughout the study
• Attend 18 visits over up to 84 weeks
• Other requirements, which the study team will review with you

This study is being conducted by Dr. Maria Hordinsky at the University of Minnesota Department Of Dermatology. For additional information, please visit the study page on ClinicalTrials.gov/study/NCT07133308 or contact the study coordinator: 612-625-2624 or [email protected]

________________________________________________________________________________________________

Study Title: 

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years to Less than 18 Years of Age with Alopecia Areata

We are conducting a research study for children ages 6-17 with patchy Alopecia Areata (AA). The purpose of this research study is to learn more about the safety, tolerability and efficacy of an investigational drug called Baricitinib. This study will compare the investigational drug to a placebo (inactive substance) to see how well the investigational drug works for 136 weeks to areas affected by Alopecia Areata, including the scalp and eyelashes and eyebrows.

Participant requirements:

• Children ages 6-17 who are in good health
• Diagnosed with patchy Alopecia Areata for at least one year
• A greater than 50% hair loss
• Must be willing to stop using other types of medications to treat AA throughout the study
• Other requirements, which the study team will review with you

This study is being conducted by Dr. Maria Hordinsky at the University of Minnesota Department of Dermatology. For additional information, please call the study coordinator: 612-625-2624 or email: [email protected]

________________________________________________________________________________________________

Study Title: 

Evaluation of Microbiota Transplant Therapy in Patients with Alopecia Areata

We are conducting a research study on individuals with moderate to severe Alopecia Areata. The purpose of this study is to determine if microbiota transplant therapy (MTT) versus a placebo is an effective treatment for patients with Alopecia Areata.

Participant requirements:

• Adults up to 75 years old who are in good health
• Diagnosed with severe or very severe Alopecia Areata and have greater than or equal to 30% scalp hair loss
• Must be willing to stop using other types of medications to treat Alopecia Areata throughout the study
• Attend 11 in-person visits over 54 weeks
• Other requirements, which the study team will review with you

This study is being conducted by Dr. Maria Hordinsky and Dr. John Meisenheimer in the University of Minnesota Department of Dermatology. For additional information, please visit the study page on Study Finder. Contact the study coordinator by phone: 612-626-0249, or email: [email protected]

There are no active Androgenetic Alopecia studies at this time. Please check back again in the future.

Study Title: 

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris

We are conducting a research study on adults with Lichen Planopilaris. The purpose of this study is to determine the safety and efficacy of investigational brepocitinib (a tyrosine kinase [TYK]2/Janus kinase [JAK]1 inhibitor) in adult participants with active, moderate to severe lichen planopilaris (LPP). 

This study will be separated into 2 parts: a 24 week placebo controlled period followed by a 28 week treatment extension and a one month follow up for a total study duration of 56 weeks.

Participant requirements:

• Women and Men over the age of 18 at the time of consent
• Active to moderate severe Lichen Planopilaris
• History of intolerance to any JAK inhibitor
• Other requirements the study team will discuss with you

This study is being conducted by Dr. Maria Hordinsky at the University of Minnesota Department Of Dermatology. For additional information, please contact the study coordinator: 612-625-2624 or [email protected]

Study Title: Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

There are no active Urticaria studies at this time. Please check back again in the future.